Table 2 Clinical characteristics and analysed variables of patients for whom the T2Dx assay was performed in addition to standard blood culture
Variablesa | Total of patients (n = 49) | T2-positive group (n = 18) | T2-negative group (n = 31) |
|---|---|---|---|
Demographic information | |||
Age (years), mean (SD) | 62.3 (16.6) | 59.7 (21.1) | 63.8 (13.5) |
Men | 36 (73.4) | 13 (72.2) | 23 (74.2) |
Patient’s co-morbidities | |||
Chronic kidney disease | 11 (22.4) | 3 (16.6) | 8 (25.8) |
Hypertension | 29 (59.1) | 9 (50.0) | 20 (64.5) |
Diabetes | 12 (24.4) | 3 (16.6) | 9 (29.0) |
Ischaemic heart disease | 15 (30.6) | 4 (22.2) | 11 (35.4) |
Neurological disease | 8 (16.3) | 4 (22.2) | 4 (12.9) |
COPD | 4 (8.1) | 1 (5.5) | 3 (9.6) |
Obesity | 7 (14.2) | 1 (5.5) | 6 (19.3) |
Cancer (all) | 12 (24.4) | 6 (33.3) | 6 (19.3) |
Solid cancer | 8 (16.3) | 4 (22.2) | 4 (12.9) |
Haematological cancer | 4 (8.1) | 2 (11.1) | 2 (6.4) |
Hospitalisation area | |||
Intensive care unit | 31 (63.2) | 11 (61.1) | 20 (64.5) |
Medical unit | 14 (28.5) | 5 (27.8) | 9 (29.1) |
Surgical unit | 4 (8.1) | 2 (11.1) | 2 (6.4) |
Primary site of BSI | |||
Respiratory | 19 (38.7) | 8 (44.4) | 11 (35.4) |
Urinary | 5 (10.2) | 3 (16.6) | 2 (6.4) |
Abdominal | 9 (18.3) | 4 (22.2) | 5 (16.1) |
Heart | 2 (4.1) | 0 | 2 (6.4) |
Skin and soft tissue | 3 (6.1) | 2 (11.1) | 1 (3.2) |
Unknown | 11 (22.4) | 1 (5.5) | 10 (32.2) |
Hospitalisation data | |||
Length of hospitalisation (days), mean (SD) | 20.0 (18.8) | 16.8 (11.1) | 21.8 (22.1) |
Time from admission to infection (days), mean (SD) | 14.4 (16.5) | 16.0 (15.6) | 13.5 (17.2) |
Time from infection to discharge/death (days), mean (SD) | 34.4 (28.3) | 32.7 (14.9) | 35.3 (33.9) |
Miscellaneous | |||
PCT (ng/mL), mean (SD) | 19.1 (46.0) | 18.6 (42.8) | 19.3 (48.4) |
Mechanical ventilation | 29 (59.1) | 10 (55.5) | 19 (61.2) |
Inotrope drugs | 33 (67.3) | 9 (50.0) | 24 (77.4) |
ECMO | 9 (18.3) | 4 (22.2) | 5 (16.1) |
CVVH | 10 (20.4) | 2 (11.1) | 8 (25.8) |
21-day mortality | 15 (30.6) | 4 (22.2) | 11 (35.4) |